Acute COVID-19 severity markers predict post-COVID new-onset psychiatric disorders: A 2-year cohort study of 34,489 patients
- PMID: 39284906
- DOI: 10.1038/s41380-024-02739-7
Acute COVID-19 severity markers predict post-COVID new-onset psychiatric disorders: A 2-year cohort study of 34,489 patients
Abstract
New-onset psychiatric disorders are frequent after COVID-19. We aim to determine whether acute COVID-19 severity markers can predict post-COVID new-onset psychiatric disorders. We conducted an electronic health records (EHR) cohort study of patients hospitalized for COVID-19 and without any known history of psychiatric disorders. Patients were included between January 2020 and September 2022 in one of the 36 university hospitals of the Assistance Publique - Hôpitaux de Paris. Acute COVID-19 clinical and biological severity markers were recorded during hospitalization for COVID-19. Psychiatric ICD-10 diagnoses were recorded up to 2 years and 9 months after hospitalization for COVID-19. Predictors of post-COVID new-onset psychiatric disorders were identified based on Cox regression models and sensitivity analyses. Predictive scores were built and tested in age- and sex-stratified populations. A total 34,489 patients hospitalized for COVID-19 were included; 3717 patients (10.8%) had at least one post-COVID new-onset psychiatric disorder. Hospital stay >7 days (HR = 1.72, 95%CI [1.59-1.86], p < 0.001), acute delirium (HR = 1.49, 95%CI [1.28-1.74], p < 0.001), elevated monocyte count (HR = 1.14, 95%CI [1.06-1.23], p < 0.001) and elevated plasma CRP (HR = 0.92, 95%CI [0.86-0.99], p = 0.04) independently predicted post-COVID new-onset psychiatric disorders. Sensitivity analyses confirmed hospital stay >7 days, acute delirium, and elevated monocyte count as predictors. Predictive scores based on these variables had good 12-month positive predictive values, up to 7.5 times more accurate than random in women < 65 years. In conclusion, hospital stay >7 days, acute delirium, and elevated monocyte count during acute COVID-19 predict post-COVID new-onset psychiatric disorders.
© 2024. The Author(s), under exclusive licence to Springer Nature Limited.
Conflict of interest statement
Competing interests: Bruno Falissard has been a consultant or speaker for Abbvie, Actelion, Allergan, Almirall, Alnylam, Amgen, Astellas, Astrazeneca, Bayer, Biogen, Biopecs, Bioproject, Biotronik, BMS, Boehringer, Celgène, Daiichi-Sankyio, Ethypharm, Forestlab, Genevrier, Genzyme, Gilead, Grünenthal, GSK, Idorsia, IMS, Indivior, IQVIA, JNJ, Léo, Lilly, Lundbeck, Menarini, MSD, Novartis, Novonordisk, Otsuka, Pfizer, Pierre-Frabre, Recordati, Roche, SANOFI, Servier, Takeda, UCB, ViiV, and Wellmera outside the submitted work. Laurent Becquemont has been a speaker Sanofi Genzyme out of the submitted work. Matthieu Gasnier, Pierre Pinson, Emmanuelle Corruble, Nathanaël Beeker, Camille Truong-Allie and Romain Colle have no conflict of interest. Ethics approval and consent to participate: All methods were performed in accordance with the relevant guidelines and regulations. This study was approved by the Institutional Review Board of the AP-HP clinical data warehouse (“Entrepôt de Données de Santé (EDS)”, IRB number: IRB00011591). Informed consent was obtained from all participants
Similar articles
-
6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records.Lancet Psychiatry. 2021 May;8(5):416-427. doi: 10.1016/S2215-0366(21)00084-5. Epub 2021 Apr 6. Lancet Psychiatry. 2021. PMID: 33836148 Free PMC article.
-
COVID-19 and Risk for Mental Disorders Among Adults in Denmark.JAMA Psychiatry. 2023 Aug 1;80(8):778-786. doi: 10.1001/jamapsychiatry.2023.1265. JAMA Psychiatry. 2023. PMID: 37223890 Free PMC article.
-
Association of post-COVID phenotypic manifestations with new-onset psychiatric disease.Transl Psychiatry. 2024 Jun 8;14(1):246. doi: 10.1038/s41398-024-02967-z. Transl Psychiatry. 2024. PMID: 38851761 Free PMC article.
-
Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic.Lancet Psychiatry. 2020 Jul;7(7):611-627. doi: 10.1016/S2215-0366(20)30203-0. Epub 2020 May 18. Lancet Psychiatry. 2020. PMID: 32437679 Free PMC article.
-
Prevalence of the Most Frequent Neuropsychiatric Diagnoses in Hospitalized SARS-CoV-2 Patients Evaluated by Liaison Psychiatry: Cross-Sectional Study.Acta Med Port. 2022 Jun 1;35(6):425-432. doi: 10.20344/amp.16410. Epub 2022 Feb 16. Acta Med Port. 2022. PMID: 35171094 Review.
References
-
- CDC. COVID Data Tracker. Centers for Disease Control and Prevention. 2020. https://covid.cdc.gov/covid-data-tracker .
-
- COVID-19 Mental Disorders Collaborators. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet. 2021;398:1700–12. - DOI
-
- Clift AK, Ranger TA, Patone M, Coupland CAC, Hatch R, Thomas K, et al. Neuropsychiatric ramifications of severe COVID-19 and other severe acute respiratory infections. JAMA Psychiatry. 2022. https://doi.org/10.1001/jamapsychiatry.2022.1067 .
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous